BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T130000
DTEND;TZID=Europe/Stockholm:20220525T140000
DTSTAMP:20260403T230739
CREATED:20220507T134201Z
LAST-MODIFIED:20220510T114934Z
UID:72461-1653483600-1653487200@www.scilifelab.se
SUMMARY:A novel\, antibody-based radiopharmaceutical for advanced thyroid cancer
DESCRIPTION:Presenter: Dr Marika Nestor\, Department of Immunology\, genetics and pathology\, Uppsala University\, Sweden \n\n\n\nMolecular radiotherapy is increasingly becoming a powerhouse in the field of cancer- and radiation therapy. By targeting a structure that is abundant on tumor cells but scarce in healthy tissues\, a cancer-targeting molecule labeled with a therapeutic radionuclide can mediate the delivery of radioactivity specifically to cancer cells. This creates a targeted\, localized form of radiotherapy that combines the advantages of systemic therapy with therapeutically effective radiation. \n\n\n\nIn a collaboration with the Drug Discovery & Development platform at Science for Life Laboratory\, we have developed an antibody-based radiopharmaceutical for molecular radiotherapy of advanced thyroid carcinoma. The project spans over the whole early development chain; from preclinical innovation in the lab\, dosimetry and proof-of-concept in animal models\, to upscaled production and preparations for first-in-man studies. \n\n\n\nDr Nestor in her presentation will discuss the process from innovation to implementation of the project\, both from a research and a commercialization perspective. \n\n\n\nsign up here\n\n\n\nMarika Nestor leads a translational research group at the Department of Immunology\, Genetics and Pathology\, Uppsala University. Her research group focuses on radionuclide targeting and radiosensitization of cancer cells. She obtained her PhD at Uppsala University in 2006\, and became an Associate Professor in 2012. In 2013 she was awarded the Göran Gustafsson prize for young scientists\, in 2016 the Junior Investigator Award from the Swedish Cancer Society\, and in 2020 the Senior Investigator Award. In 2019\, she was awarded a grant from Sweden’s innovation agency VINNOVA to facilitate clinical translation of her findings\, as well as an Attractive Innovation Award by UU Innovation.
URL:https://www.scilifelab.se/event/a-novel-antibody-based-radiopharmaceutical-for-advanced-thyroid-cancer/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
END:VCALENDAR